SABS

SAB Biotherapeutics, Inc. (SABS) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies. The company's lead candidate, SAB-142, is a human anti-thymocyte globulin (hATG) in clinical development for the treatment of autoimmune type 1 diabetes (T1D). The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Raise: The company completed a March 2026 Public Offering, raising approximately $86.4 million in net proceeds (including partial exercise of the underwriters' option). This significantly increased cash and investment balances compared to the prior year.
• Operating Expenses: Total operating expenses increased by 85.7% to $20.0 million.
  • R&D Expenses: Increased 75.0% to $13.4 million, driven by higher salaries, clinical trial costs for the Phase 2b SAFEGUARD study, and stock-based compensation.
  • G&A Expenses: Increased 111.9% to $6.6 million, primarily due to increased salaries, professional fees, and stock-based compensation.
• Net Loss: Net loss widened to $18.9 million from $5.2 million, primarily due to increased operating costs and a reversal of the gain on warrant liabilities seen in the prior year.
• Warrant Liabilities: The company recorded a loss of $0.48 million on changes in fair value of warrant liabilities, compared to a gain of $5.04 million in Q1 2025.
• Interest Income: Increased significantly to $1.05 million (from $0.06 million) due to higher cash and investment balances earning interest.

Guidance, Outlook, and Risks

• Clinical Progress: The Phase 2b SAFEGUARD study for SAB-142 is ongoing with enrollment across multiple sites. In April 2026, the FDA confirmed that C-peptide area under the curve (AUC) may serve as a surrogate endpoint for accelerated approval.
• Liquidity: Management states that existing resources are sufficient to cover operating cash needs for at least the twelve months following the report date. The company anticipates continuing losses as it advances clinical development.
• Subsequent Events:
  • In April 2026, underwriters partially exercised the remaining option from the March offering, generating an additional ~$2.2 million.
  • Entered a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for SAB-142 manufacturing, with a minimum aggregate spend of $36 million following FDA approval.
• Risks: The company has no commercially approved products and relies on successful clinical trials and regulatory approvals. It faces risks related to capital requirements, clinical trial outcomes, and competition.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the ~$217.6 million in liquid assets (cash + investments) against the current burn rate of ~$14.3 million per quarter in operating cash usage.
• Phase 2b Enrollment: Monitor the pace of patient enrollment in the SAFEGUARD study and any updates on the FDA's acceptance of the C-peptide surrogate endpoint.
• Manufacturing Commitment: Review the terms of the new agreement with Emergent BioSolutions, specifically the $36 million minimum spend obligation post-approval.
• Dilution: Note the significant increase in outstanding shares (from ~47.6 million to ~75.7 million) due to the March 2026 offering and preferred stock conversions.
• Warrant Liability Volatility: Monitor the fair value of outstanding warrant liabilities, which can cause significant non-cash fluctuations in net income.